Table 1.
Clinical and laboratory characteristics of AML patients and controls.
| Laboratory characteristic | Patients | Controls | P value |
|---|---|---|---|
| Median age (min–max) | 39 (18-95) | 40 (24-68) | 0.97 |
| Gender (male/female) | 29/18 | 4/2 | |
| Median WBC (∗10 mL) | 63 | 7.5 | 0.005 |
| Median hemoglobin (gr/L) | 8 | 13.5 | 0.0005 |
| Plt (∗10) | 30 | 274.5 | 0.0003 |
| FAB classification | — | 0.4 | |
| M0 | 6 | — | |
| M1 | 7 | — | |
| M2 | 10 | — | |
| M3 | 2 | — | |
| M4 | 16 | — | |
| M5 | 6 | — | |
| Patient karyotype∗ | |||
| NK-AML | 20 | NA | |
| Favorable | 3 | NA | |
| Unfavorable | 8 | NA | |
| Intermediate | 1 | NA | |
| Unclassified | 3 | NA | |
| Missed (unknown) | 12 | NA |
∗Cytogenetic classification was based on WHO criteria. NK-AM: normal karyotype-AML. The meaning of a favorable response generally indicates an overall survival rate of about 50-60% for patients who achieve remission after therapy for AML with abnormalities involving chromosome 16,t(8;21), and perhaps even for the group that has deletion involving the long arm of chromosome 9. AML patients with unfavorable-risk cytogenetic abnormalities account for 16-30% of younger adult patients and have poor response to standard treatment, with only 32-55% achieving a complete response. The intermediate-risk cytogenetic subclass of AML includes cytogenetically normal (CN) and AML with other cytogenetic abnormalities and accounts for approximately 60% of all AML patients. NA: not available.